Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04408937 · ClinicalTrials.gov registry record · Phase 1
The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT04408937 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT04408937, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether dosing tropifexor is safe and tolerable.
Interventions
- DRUG Placebo
- DRUG triopifexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2020-05-29 |
| Est. Completion | 2020-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04408937
The ClinicalTrials.gov registry entry for NCT04408937 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04408937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04408937 about?
NCT04408937 is a clinical study titled "The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.". The purpose of this study is to determine whether dosing tropifexor is safe and tolerable.
What is the current status of trial NCT04408937?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2020-05-29. Estimated completion is 2020-11-04.
What interventions are being tested in trial NCT04408937?
The interventions under investigation include: Placebo (DRUG), triopifexor (DRUG).
Who is sponsoring clinical trial NCT04408937?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.